A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/24/2002	WO2002051848A3 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002050057A8 Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
10/24/2002	WO2002048380A3 Glycosilated cationic lipids for liposomes used in drug delivery
10/24/2002	WO2002047667A3 Novel medicament compositions based on anticholinesterase drugs and on a steroid
10/24/2002	WO2002043689A3 Cosmetic, pharmaceutical and dermatological products
10/24/2002	WO2002040015A8 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
10/24/2002	WO2002032397A9 Electroprocessing in drug delivery and cell encapsulation
10/24/2002	WO2002030931A3 Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
10/24/2002	WO2002024659A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
10/24/2002	WO2002024610A3 Method for producing an antineoplastic
10/24/2002	WO2002013825A8 Novel pharmaceutical use of quinnoline derivatives
10/24/2002	WO2002006462A3 Methylated nucleotide regulation of upa gene expression
10/24/2002	WO2002003972A3 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
10/24/2002	WO2002000650A3 Novel compounds possessing antibacterial, antifungal or antitumor activity
10/24/2002	WO2002000210A3 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
10/24/2002	WO2002000164A3 Chemosensitizer
10/24/2002	WO2001085206A3 Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound
10/24/2002	WO2001077375A8 Diagnosis of diseases associated with gene regulation
10/24/2002	WO2001076568B1 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/24/2002	WO2001072315A9 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract
10/24/2002	WO2001070210A3 Methods for improving size and appearance of a wound
10/24/2002	WO2001068911A8 Diagnosis of diseases associated with the cell cycle
10/24/2002	WO2001068135A9 Compositions and methods for affecting osteogenesis
10/24/2002	WO2001060778A9 Aspirin-triggered lipid mediators
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	WO2001058439A9 Low dose modafinil for enhancement of cognitive function
10/24/2002	WO2001057189A9 Fas pathway genes
10/24/2002	WO2001053299A9 Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
10/24/2002	WO2001047529A3 Association of deoxyfructosazine and an antidiabetic agonist of the peroxysome proliferator gamma-activated receptor
10/24/2002	WO2001021135A3 Polymer conjugates of ara-c and ara-c derivatives
10/24/2002	WO2000040247A9 2-oxy-benzoxazinone derivatives for the treatment of obesity
10/24/2002	US20020156498 Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same
10/24/2002	US20020156296 Kidney disease, organ transplant
10/24/2002	US20020156293 Process for the preparation of zofenopril calcium salt
10/24/2002	US20020156292 Anticancer agents
10/24/2002	US20020156284 Crystalline form of omeprazole
10/24/2002	US20020156275 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
10/24/2002	US20020156266 Sodium phosphate cotransporter expressed on apical surface of intestinal epithelial cells (huNpt2B) and polypeptides related thereto
10/24/2002	US20020156261 Wherein secondary structure disintegrates upon attachment of the oligonucleotide to a target nucleic acid; anticarcenogenic agents, treatment of Ewing's sarcoma
10/24/2002	US20020156258 Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
10/24/2002	US20020156252 Novel Stra6 polypeptides
10/24/2002	US20020156251 Fusion protein for use in the treatment and prevention of viral diseases
10/24/2002	US20020156246 15625 receptor, a novel G-protein coupled receptor
10/24/2002	US20020156134 Inhibiting production of advanced glycosylation end products by administering a penicillamine
10/24/2002	US20020156133 Oral administration forms for administering a fixed tramadol and diclofenac combination
10/24/2002	US20020156132 Reaction product of arginine and p-aminobenzoic acid, cosmetic, and human and animal health compositions thereof
10/24/2002	US20020156131 Intravenous valproate for acute treatment of migraine headache
10/24/2002	US20020156129 Method of treating pruritus and a pharmaceutical composition for the method
10/24/2002	US20020156127 Carbamate compounds for use in the treatment of pain
10/24/2002	US20020156125 Coadministering an oral cyclosporin enhancing agent with paclitaxel or docetaxel
10/24/2002	US20020156124 Paclitaxel, a solvent, a surfactant, a substituted cellulosic polymer, and a P-glycoprotein inhibitor; supersaturation of a microemulsion upon contact with water
10/24/2002	US20020156123 Novel pharmaceutical compositions for modulating angiogenesis
10/24/2002	US20020156122 Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
10/24/2002	US20020156121 Methods for treating patients suffering from drug dependencies which leads to plasma melatonin deficiencies
10/24/2002	US20020156118 Bis-indol-3-yl 3-pyrroline derivatives and paclitaxel
10/24/2002	US20020156116 Antiproliferative agents for disorders with GRB-2 adaptor protein function; treating diabetes, insulin resistance, insulin deficiency and insulin allergy
10/24/2002	US20020156113 Farnesyl transferase inhibitors; anticancer agents
10/24/2002	US20020156112 Endostatin-like angiogenesis inhibition
10/24/2002	US20020156111 Substituted bicyclic compounds
10/24/2002	US20020156109 1,4-dihydropyridine derivative with a guaiacoxypropanolamine and/or phenoxypropanolamine moiety
10/24/2002	US20020156106 Use of insulin sensitisers for treating renal diseases
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156103 Process for purifying 6- methoxy omeprazole
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156101 Use for pain management
10/24/2002	US20020156100 1-deoxy-galactonojirimycin and related compounds used to treat fabry disease
10/24/2002	US20020156099 1-acyl-piperidine substance p antagonist; used to treat central nervous system disorders and respiratory diseases
10/24/2002	US20020156098 Antiprotozoa agents, parasiticides
10/24/2002	US20020156097 Pharmaceuticals
10/24/2002	US20020156095 Treatment of depression, anxiety, psychosis, obesity, pain, Parkinson's disease, Alzheimer's disease, neurodegenerative diseases, movement disorders, respiratory diseases, inflammatory diseases, neuropathy, immune disorders, etc.
10/24/2002	US20020156094 Sulfonamide interleukin-1beta converting enzyme inhibitors
10/24/2002	US20020156093 (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-y l) acetonitrile or its salt to treat psychological disorders
10/24/2002	US20020156091 Dosing interval of the nimesulide overlaps with that of the oxycodone to reduce the amount of oxycodone needed to provide an effect
10/24/2002	US20020156090 Estrogen agonist/antagonist to prevente myocardial infarction or stroke, maintaining or improving vascular reactivity, treat renal failure, peripheral arterial occlusive disease, coronary artery disease, or raynaud's phenomenon
10/24/2002	US20020156089 Use of CRF antagonists and related compositions
10/24/2002	US20020156088 Using dipyridamole or mopidamol in doses lower than those needed to directly inhibit platelet aggregation alone or with a substance that increases nitric oxide production such as a hmg coa reuctase inhibitor
10/24/2002	US20020156086 Cetirizine, an individual optical isomer or a salt thereof
10/24/2002	US20020156085 1,4-Disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers
10/24/2002	US20020156084 Use of N-benzyl piperazine and analogues as quality of life enhancers
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156080 Reducing intraocular pressure by administering a heteroaryl onium derivative
10/24/2002	US20020156079 Antiulcer, antibacterial activity against Helicobacter pylori
10/24/2002	US20020156078 Use of molindone to treat oppositional defiant disorder and conduct disorder
10/24/2002	US20020156074 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors
10/24/2002	US20020156073 Intraocular pressure decreasing with a heterocycle compound
10/24/2002	US20020156072 Thiazine oxazolidinone
10/24/2002	US20020156071 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors
10/24/2002	US20020156070 Felbamate derived compounds
10/24/2002	US20020156069 Benzo thiadiazine matrix metalloproteinase inhibitors
10/24/2002	US20020156068 Anti-psychosis combination
10/24/2002	US20020156067 New drug combinations
10/24/2002	US20020156066 Preparing a solution of paroxetine hydrochloride or sertaline hydrochloride and a water-soluble carrier in a co-solvent of a volatile solvent and water, and drying the solution
10/24/2002	US20020156065 Medicament and method for the remediation of aberrant fibrotic tissue masses with topical calcium channel blocker preparations
10/24/2002	US20020156064 Compounds and their use as PDE inhibitors
10/24/2002	US20020156061 Administering to a mammal a matrix metalloproteinase inhibiting amount of derivatives of isophthalic acid, isophthalic acid ester or isothalamide compounds to treat cancer, rheumatic arthritis atherosclerosis and osteoporosis
10/24/2002	US20020156060 B-ring estratriene diols
10/24/2002	US20020156059 Selective estrogen replacement therapy to treat menpausal symptoms
10/24/2002	US20020156057 Hypotensive agents for those suffering from aldosteronism; canrenone, spironolactone and amiloride
10/24/2002	US20020156056 Fast-dispersing dosage form of apomorphine and testosterone that disintegrates in the oral cavity within 1-30 seconds

1 ... 5670 5671 5672 5673 5674 5675 5676 5677 5678 5679 5680 5681 5682 5683 5684 5685 5686 5687 5688 5689 5690 ... 7860